Delivery Order SPE2DB24D2101-SPE2DB25FKNGP
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Tezspire 210 mg/1.91 mL syringes valued at $2,343.59, with an ultimate completion date of October 1, 2025. This non-competitive delivery order utilizes firm fixed price pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a $7,030.77 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Tezspire 210 mg/1.91 ml pens. The contract, which carries a firm fixed price structure with no set-aside designation, is scheduled for completion by August 12, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectables. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion deadline of August 28, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $4.7K delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injections. This competitively awarded, firm fixed-price contract carries an ultimate completion date of September 29, 2025, and will be fulfilled at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $18,748.72 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with performance completion by September 30, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger federal contracting vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania....
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $14,061.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract, which is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), carries an ultimate completion date of September 3, 2025, and involves no set-aside designation....
- The Defense Logistics Agency (DLA) awarded a $9,374.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Tezspire 210 mg/1.91 mL syringes. The award, issued on August 14, 2025, is scheduled for completion by September 5, 2025, with performance to be completed at the vendor's Conshohocken, Pennsylvania location. This delivery order represents a non-set-aside, competitively awarded procurement and is issued as a child contract under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a $35,153.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of September 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $9,374.36 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with completion scheduled for September 29, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite...
- The Defense Logistics Agency awarded a $9,374.36 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Tezspire 210 mg/1.91 mL syringes. This is a firm fixed-price delivery order with an ultimate completion date of June 23, 2025, and represents a non-competitive set-aside contract. The pharmaceutical product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKNGPDelivery Order
The Defense Logistics Agency awarded a $7,030.77 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Tezspire 210 mg/1.91 mL syringes. The contract is firm fixed price with an ultimate completion date of August 29, 2025, and carries no set-aside designation, indicating it was competitively awarded. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency. The company maintains an extensive portfolio of federal contract awards encompassing a wide spectrum of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. The current delivery order for Tezspire—a biologic medication used in respiratory disease treatment—reflects the company's continued role in fulfilling specialized pharmaceutical requirements for the Department of Defense's healthcare network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.0k | 8/8/25 |